---
title: InsightRX for Life Sciences
description: Optimize drug dosing with InsightRX's precision dosing and AI-native analysis tools, enhancing patient safety and regulatory compliance throughout clinical development.
---
[](https://www.insight-rx.com/?hsLang=en)
- For Providers
- Solutions
- [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd?hsLang=en)
- [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future?hsLang=en)
- Products
- [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova?hsLang=en)
- [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo?hsLang=en)
- [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules?hsLang=en)
- [For Life Sciences](https://www.insight-rx.com/life-sciences)
- Overview
- [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences)
- Products
- [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova?hsLang=en)
- [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra?hsLang=en)
- Platform
- [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning?hsLang=en)
- [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations?hsLang=en)
- [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory?hsLang=en)
- [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support?hsLang=en)
- Resources
- Science
- [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science?hsLang=en)
- [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications?hsLang=en)
- [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova?hsLang=en)
- Explore
- [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories?hsLang=en)
- [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers?hsLang=en)
- [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software?hsLang=en)
- [Blog](https://blog.insight-rx.com/resources?hsLang=en)
- [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources?hsLang=en)
- [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation&hsLang=en)
- [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership&hsLang=en)
- Company
- About
- [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about?hsLang=en)
- [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership?hsLang=en)
- [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board?hsLang=en)
- [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers?hsLang=en)
- [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers?hsLang=en)
- Press
- [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases?hsLang=en)
- [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases&hsLang=en)
- [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media&hsLang=en)
[](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574)
[](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574)
InsightRX for Life Sciences
# Precision dosing and PK/PD analysis for clinical development.
Regulatory agencies are raising the bar for dose optimization across drug development. InsightRX gives biopharma teams the tools to meet that standard, from first-in-human through regulatory submission.
1. [Home](https://www.insight-rx.com?hsLang=en)
2. InsightRX for Life Sciences
## Precision dosing meets AI-native analysis
InsightRX Nova and Astra bring precision dosing and AI-native PK/PD analysis to every stage of clinical development, from first-in-human through regulatory submission:
### [Precision Dosing InsightRX Nova Bayesian dosing support for clinical trial participants. Individualize regimens from Phase I, help researchers reduce adverse events, and support participant retention.](https://www.insight-rx.com/life-sciences/nova?hsLang=en)
### [AI-Powered PK/PD Analysis InsightRX Astra AI-native analysis environment for NCA, Pop-PK, simulation, and reporting. 21 CFR Part 11 and GxP built in. No programming dependency.](https://www.insight-rx.com/life-sciences/astra?hsLang=en)
On this page
## The Capabilities: What Modern Dose Optimization Requires
Meeting modern regulatory expectations for dose optimization requires more from early-phase programs than traditional Phase I designs. It calls for population PK modeling to characterize the dose-exposure relationship before pivotal trial design decisions are made, exposure-response analysis to identify the dose range where efficacy is observed and tolerability is acceptable, and the ability to perform patient-specific and population-level drug response simulations in real time, within clinical trials. Audit-ready data infrastructure ties it all together.
These capabilities have historically required specialized programming skills, disconnected tools, and substantial manual effort. Regulatory pressure is compressing the timeline for all of them, and raising the expectation that pharmacometricians and statisticians are involved from the start, not brought in after the fact.
> "Multi-arm, multi-dose studies will increasingly be required. Sponsors must build dose optimization into timelines and allow for iterative learning, scenario planning, and adjustments to pivotal trial designs."
>
> [Allucent, 2025](https://www.allucent.com/resources/blog/fda-project-optimus-dose-optimization-oncology-trials)
## Why the Right Dose Matters
Dose optimization is not only a regulatory story. For the patients enrolled in these trials, getting the dose right from the start has direct consequences.
High inter-patient variability means the same nominal dose produces dramatically different exposures across individuals. A dose that achieves the therapeutic target in one participant may be subtherapeutic in another, or toxic in a third. When that variability is not accounted for, adverse drug reactions accumulate, and adverse reactions are among the leading drivers of patient dropout.
> Dropout rates in Phase 3 clinical trials can often be substantial — sometimes more than 30% — with adverse drug reactions among the leading contributors.
>
> [P&T, 2013 (citing National Academies Press, 2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3684189/)
Model-informed precision dosing addresses this directly. By using population pharmacokinetic models and Bayesian estimation to individualize each participant's dose based on their actual measured concentrations and clinical characteristics, MIPD keeps more participants within the therapeutic window, helping to reduce adverse events, supporting retention, and generating cleaner exposure data for the dose-response analyses that modern regulatory guidance now requires.
InsightRX has operated in regulated clinical settings for a decade, deploying precision dosing across more than a thousand US hospitals and personalizing millions of doses in real-world clinical use. That foundation of validated models, GxP-ready infrastructure, and continuous learning is what we bring to clinical development.
## Project Optimus: A Paradigm Shift in Dose Selection
For decades, drug development has followed established paradigms for dose selection (weight-based formulas, fixed regimens, or the highest dose a patient can tolerate). These approaches worked well enough for many therapies. But modern drug development has raised the bar.
Modern therapeutics have outgrown these paradigms. Targeted small molecules, biologics, immunotherapies, antibody-drug conjugates, and cell and gene therapies operate through mechanisms where maximum biological effect is often reached at doses well below what a patient can tolerate. Many are administered over months or years, where even low-grade toxicities accumulate and drive treatment discontinuation. The dose that once made sense — the highest a patient could tolerate — no longer maps to the dose that delivers the most benefit.
Oncology has been the sharpest case. Dose selection there has historically centered on the maximum tolerated dose (MTD), a paradigm that fit cytotoxic chemotherapy but doesn't fit today's targeted and immune-modulating agents. Approximately 80% of oncology drugs approved between 2010 and August 2021 saw no further dose-ranging or refinement beyond Phase 1 dose escalation [(Cancers, 2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11202153/), meaning the vast majority were approved without systematically evaluating whether a lower dose might perform as well with better tolerability.
In 2021, the FDA's Oncology Center of Excellence launched Project Optimus to reform how doses are selected. Rather than defaulting to the MTD, sponsors are now expected to identify an optimal biological dose: the regimen that delivers therapeutic benefit with acceptable tolerability, supported by pharmacokinetic, pharmacodynamic, and efficacy evidence from early in development.
The final guidance, published in August 2024, codified these expectations. Randomized dose-finding studies comparing at least two doses are now expected in Phase I. Early engagement with the agency, ideally pre-IND or at end-of-Phase 1 meetings, is considered essential rather than optional.
Though Project Optimus began in oncology, its underlying principle is echoed across therapeutic areas: modern therapeutics require rigorous, evidence-based dose justification rather than a single tolerated dose carried forward. Regulators globally are raising expectations for dose justification, and biopharma teams across modalities are increasingly treating dose optimization as a core early-phase deliverable rather than a post-hoc question.
The consequences of not adapting are significant. The FDA has issued dose-optimization-related post-marketing requirements or commitments in 15% of oncology new molecular entity approvals since 2010 [(Samineni et al., Clinical Pharmacology & Therapeutics, 2024)](https://doi.org/10.1002/cpt.3298), pushing dose refinement into costly post-approval studies. Sponsors who do not build dose optimization into early-phase timelines face costly post-approval corrections, potential label modifications, and delayed commercialization.
> "93% of surveyed biopharma companies say Project Optimus has impacted their recent strategies for dose optimization."
>
> Samineni et al., Clinical Pharmacology & Therapeutics, 2024
### [InsightRX · Applied Clinical Trials Understanding Project Optimus InsightRX on why oncology needs a dosing redesign and what Project Optimus means for Phase I and II trial design.](https://blog.insight-rx.com/resources/understanding-project-optimus?hsLang=en)
### [InsightRX · Applied Clinical Trials Artificial Intelligence Drives Industry Response to Project Optimus InsightRX on how AI is the most essential tool for unlocking efficiencies in clinical development and ensuring the right drugs reach the right patients at the right dose.](https://blog.insight-rx.com/resources/artificial-intelligence-drives-industry-response-project-optimus?hsLang=en)
## Explore more...
Every InsightRX product and capability is built to work together, supporting precision medicine at every stage.
### [Integrate Seamlessly with Existing Clinical Systems InsightRX integrates securely with leading EDC systems and clinical data platforms, so pharmacokinetic data flows automatically into your trial records.](https://www.insight-rx.com/platform/integrations?hsLang=en)
### [Built for Regulated Clinical Environments InsightRX meets the standards clinical development demands: 21 CFR Part 11, CE marking, ISO 13485, IEC 62304, ISO 14971, and GDPR compliance for international trial deployments.](https://www.insight-rx.com/platform/security-regulatory?hsLang=en)
### [Data Science and Model Quality Every InsightRX model is rigorously validated through a structured scientific review process, ensuring clinical relevance and predictive accuracy across diverse patient populations.](https://www.insight-rx.com/data-science?hsLang=en)
Maximize therapeutic success
with precision medicine.
[](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=…)
#### What We Do
##### For Providers
- [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova?hsLang=en)
- [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo?hsLang=en)
- [Drug Modules](https://www.insight-rx.com/provider/drug-modules?hsLang=en)
##### For Life Sciences
- [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova?hsLang=en)
- [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra?hsLang=en)
- [Companion Applications](https://www.insight-rx.com/life-sciences/nova?hsLang=en#companion-applications)
#### How We Do It
##### Platform
- [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning?hsLang=en)
- [Integrations](https://www.insight-rx.com/platform/integrations?hsLang=en)
- [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory?hsLang=en)
- [Success & Support](https://www.insight-rx.com/platform/success-support?hsLang=en)
##### Science
- [Data Science](https://www.insight-rx.com/data-science?hsLang=en)
- [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications?hsLang=en)
#### Information
##### Resources
- [Success Stories](https://www.insight-rx.com/success-stories?hsLang=en)
- [White Papers](https://www.insight-rx.com/white-papers?hsLang=en)
- [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software?hsLang=en)
- [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova?hsLang=en)
##### Blog
- [All Posts](https://blog.insight-rx.com/resources?hsLang=en)
- [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation&hsLang=en)
- [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership&hsLang=en)
#### About
- [Our Story](https://www.insight-rx.com/about?hsLang=en)
- [Leadership](https://www.insight-rx.com/leadership?hsLang=en)
- [Advisory Board](https://www.insight-rx.com/advisory-board?hsLang=en)
- [Our Customers](https://www.insight-rx.com/customers?hsLang=en)
- [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases&hsLang=en)
- [Media](https://blog.insight-rx.com/press-releases?section=media&hsLang=en)
- [Careers](https://www.insight-rx.com/careers?hsLang=en)
- [Contact](https://www.insight-rx.com/contact-us?hsLang=en)
---
InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1.
InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance.
740-05000-REC-01 · 08/2025
---
[](https://www.insight-rx.com/?hsLang=en)
548 Market Street
#88083
San Francisco, CA 94104
---
© 2026 InsightRX, Inc. All rights reserved.
[Privacy Policy](https://www.insight-rx.com/privacy-policy?hsLang=en) Cookie Preferences
```json
{
"@context" : "https://schema.org",
"@type" : "BreadcrumbList",
"itemListElement" : [ {
"@type" : "ListItem",
"item" : {
"@id" : "https://www.insight-rx.com"
},
"name" : "Home",
"position" : 1
}, {
"@type" : "ListItem",
"item" : {
"@id" : "https://www.insight-rx.com/life-sciences"
},
"name" : "InsightRX for Life Sciences",
"position" : 2
} ]
}
```